Education
About Us
Working with TipRanks
Follow Us
Regeneron Pharmaceuticals (REGN)
:REGN
REGN Analyst Ratings
Strong Buy
16 Buy
3 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
REGN Stock 12 Month Forecast
Average Price Target
$956.25
▲(44.67% Upside)
| Highest Price Target$1,182 | Average Price Target$956.25 | Lowest Price Target$575.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
BMO Capital
Reiterated
03/14/25
TD Cowen
Reiterated
03/06/25
Canaccord Genuity
Reiterated
02/25/25
Guggenheim
Reiterated
02/11/25
Evercore ISI
Reiterated
02/07/25
Leerink Partners
Upgraded
02/06/25
Bank of America Securities
Reiterated
02/05/25
Truist Financial
Reiterated
02/05/25
Robert W. Baird
Reiterated
02/05/25
Oppenheimer
$950
Buy
43.72%
Upside
Reiterated
02/05/25
Oppenheimer Sticks to Their Buy Rating for Regeneron (REGN)
Wells Fargo
$900
Buy
36.16%
Upside
Reiterated
02/04/25
Regeneron: Strategic Growth and Pipeline Catalysts Justify Buy Rating
Morgan Stanley
$1,185→$1,150
Buy
73.98%
Upside
Reiterated
02/04/25
Regeneron Pharma (REGN) PT Lowered to $1,150 at Morgan StanleyMorgan Stanley analyst Matthew Harrison lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,150.00 (from $1,185.00) while maintaining a Overweight rating.
RBC Capital
$1,059→$1,045
Buy
58.09%
Upside
Reiterated
02/04/25
RBC Capital Reaffirms Their Buy Rating on Regeneron (REGN)
Goldman Sachs
$1,185→$1,182
Buy
78.82%
Upside
Reiterated
02/03/25
Regeneron: Buy Rating Amidst Challenges and Opportunities for GrowthWe see upside potential per execution on favorable near-term Eylea HD label-enhancing catalysts and the pipeline (including obesity, thrombosis, severe food allergy, and oncology, among others) albeit recognize risks. On the 4Q earnings report, we look to management commentary on Eylea 2mg trough levels to address the wide range of Street estimates (FY25 US company-compiled consensus range of $2.1-$4.0bn for Eylea franchise) which could remove an overhang if provided. REGN’s US Eylea franchise accounts for ~42% of REGN’s sales (as of FY24) and treats the largest retinal disease market: wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR).
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
BMO Capital
Reiterated
03/14/25
TD Cowen
Reiterated
03/06/25
Canaccord Genuity
Reiterated
02/25/25
Guggenheim
Reiterated
02/11/25
Evercore ISI
Reiterated
02/07/25
Leerink Partners
Upgraded
02/06/25
Bank of America Securities
Reiterated
02/05/25
Truist Financial
Reiterated
02/05/25
Robert W. Baird
Reiterated
02/05/25
Oppenheimer
$950
Buy
43.72%
Upside
Reiterated
02/05/25
Oppenheimer Sticks to Their Buy Rating for Regeneron (REGN)
Wells Fargo
$900
Buy
36.16%
Upside
Reiterated
02/04/25
Regeneron: Strategic Growth and Pipeline Catalysts Justify Buy Rating
Morgan Stanley
$1,185→$1,150
Buy
73.98%
Upside
Reiterated
02/04/25
Regeneron Pharma (REGN) PT Lowered to $1,150 at Morgan StanleyMorgan Stanley analyst Matthew Harrison lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,150.00 (from $1,185.00) while maintaining a Overweight rating.
RBC Capital
$1,059→$1,045
Buy
58.09%
Upside
Reiterated
02/04/25
RBC Capital Reaffirms Their Buy Rating on Regeneron (REGN)
Goldman Sachs
$1,185→$1,182
Buy
78.82%
Upside
Reiterated
02/03/25
Regeneron: Buy Rating Amidst Challenges and Opportunities for GrowthWe see upside potential per execution on favorable near-term Eylea HD label-enhancing catalysts and the pipeline (including obesity, thrombosis, severe food allergy, and oncology, among others) albeit recognize risks. On the 4Q earnings report, we look to management commentary on Eylea 2mg trough levels to address the wide range of Street estimates (FY25 US company-compiled consensus range of $2.1-$4.0bn for Eylea franchise) which could remove an overhang if provided. REGN’s US Eylea franchise accounts for ~42% of REGN’s sales (as of FY24) and treats the largest retinal disease market: wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR).
Best Analysts Covering Regeneron
Which Analyst Should I Follow If I Want to Buy REGN and Sell After:
1 Month
xxx
Success Rate
23/41 ratings generated profit
Average Return
+1.11%
assigned a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.10% of your transactions generating a profit, with an average return of +1.11% per trade.
3 Months
xxx
Success Rate
11/19 ratings generated profit
Average Return
+2.15%
upgraded a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +2.15% per trade.
1 Year
Success Rate
13/19 ratings generated profit
Average Return
+13.24%
upgraded a buy rating 2 months ago
Copying David Risinger's trades and holding each position for 1 Year would result in 68.42% of your transactions generating a profit, with an average return of +13.24% per trade.
2 Years
xxx
Success Rate
13/19 ratings generated profit
Average Return
+14.81%
upgraded a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 68.42% of your transactions generating a profit, with an average return of +14.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
REGN Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
2
7
17
21
16
Buy
52
31
21
17
19
Hold
10
9
11
9
8
Sell
2
2
3
3
2
Strong Sell
0
0
0
0
0
total
66
49
52
50
45
Each month's total comprises the sum of three months' worth of ratings.
REGN Financial Forecast
REGN Stock Forecast FAQ
What is REGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Regeneron Pharmaceuticals’s 12-month average price target is $956.25.
What is REGN’s upside potential, based on the analysts’ average price target?
Regeneron Pharmaceuticals has 44.67% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is REGN a Buy, Sell or Hold?
Regeneron Pharmaceuticals has a consensus rating of Strong Buy which is based on 16 buy ratings, 3 hold ratings and 1 sell ratings.
What is Regeneron Pharmaceuticals’s price target?
The average price target for Regeneron Pharmaceuticals is $956.25. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1,182.00 ,the lowest forecast is $575.00. The average price target represents 44.67% Increase from the current price of $661.
The highest analyst price target is $1,182.00 ,the lowest forecast is $575.00. The average price target represents 44.67% Increase from the current price of $661.
What do analysts say about Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
How can I buy shares of REGN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.